STAAHealthcare · Medical Instruments & SuppliesThe 12 Wall Street analysts covering STAAR Surgical Co. hold a median 12-month price target of $28 — +19.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 80 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores STAAR Surgical Co. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (99): Sales and profits are climbing, and climbing faster than before.
Accruals (37): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on STAA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +19.0% from it.
Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Aug 2026 | Stifel | Maintains | Hold | $31 → $28 |
| 13 Aug 2026 | UBS | Maintains | Sell | $20 → $19 |
| 13 Aug 2026 | Wedbush | Maintains | Outperform | $40 → $37 |
| 4 Aug 2026 | Wedbush | Reiterates | Outperform | $40 |
| 4 Aug 2026 | Wedbush | Reiterates | Outperform | — |
| 28 July 2026 | UBS | Initiates | Sell | — |
| 28 July 2026 | UBS | Initiates | Sell | $20 |
| 22 July 2026 | Wedbush | Reiterates | Outperform | — |
| 22 July 2026 | Wedbush | Reiterates | Outperform | $40 |
| 16 July 2026 | Wedbush | Reiterates | Outperform | — |
| 16 July 2026 | Wedbush | Reiterates | Outperform | $40 |
| 29 May 2026 | Wedbush | Reiterates | Outperform | — |
| 15 May 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 14 May 2026 | Canaccord Genuity | Maintains | Buy | — |
| 14 May 2026 | Mizuho | Maintains | Neutral | — |
| 14 May 2026 | Piper Sandler | Maintains | Neutral | — |
| 14 May 2026 | Stifel | Maintains | Hold | — |
| 14 May 2026 | Wedbush | Upgrade | Outperform | — |
| 9 Apr 2026 | Canaccord Genuity | Upgrade | Buy | — |
| 9 Apr 2026 | Wedbush | Maintains | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. STAA appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 3% of US stocks
Cheaper than 37% of US stocks
Cheaper than 32% of US stocks
Cheaper than 16% of US stocks
Higher than 94% of US stocks
Higher than 86% of US stocks
Higher than 86% of US stocks
Higher than 65% of US stocks
Higher than 50% of US stocks
Higher than 45% of US stocks
Higher than 79% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own STAAR Surgical Co. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research published a review of STAAR Surgical's (STAA) international revenue performance and how those trends influence Wall Street analysts' forecasts and the stock's future prospects.
Why it matters — A STAA watcher would care because international revenue trends are central to analysts' predictions about the company's future performance and stock outlook.
STAAR Surgical reported second-quarter 2026 net sales of $93.5 million, up 111% from $44.3 million a year earlier. CEO Warren Foust attributed the growth to contributions from China, the Americas and parts of Europe, and called it the company's strongest first half of revenue performance.
Why it matters — The report highlights strong revenue growth across key markets, indicating robust demand for STAAR Surgical's products during the period.
STAAR Surgical Company (STAA) published the transcript of its Q2 2026 earnings call, as covered by Seeking Alpha. The item presents the transcript of the company's second-quarter 2026 earnings discussion.
Why it matters — A STAA watcher would care because the transcript provides management's direct commentary on the company's quarterly performance and outlook.
Staar Surgical reported quarterly earnings of $0.31 per share, surpassing the Zacks Consensus Estimate of $0.21 per share. This compares with a loss of $0.07 per share in the same quarter a year ago.
Why it matters — The company beat analyst expectations for both earnings and revenue, marking a notable improvement from a year-ago loss.
STAAR Surgical reported second quarter 2026 results for the period ended July 3, 2026. Net sales totaled $93.5 million, up 111% year-over-year, with China sales of $52.3 million up over 100% year-over-year and up 10% sequentially, while sales excluding China grew 6.0% year-over-year to $41.2 million. APAC sales rose 189% year-over-year, including ex-China growth.
Why it matters — STAA watchers would track this quarter as it shows a major year-over-year surge in total and China net sales, a key driver of the company's performance in its core phakic IOL market.
The 12 Wall Street analysts covering STAAR Surgical Co. have a median 12-month price target of $28, with estimates ranging from $19 to $37. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 12 analysts covering STAAR Surgical Co., 3 rate it a Buy, 8 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks STAAR Surgical Co. 80 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, STAAR Surgical Co. ranks 80 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).
No one can know that. What the data says: the median 12-month target from 12 analysts implies +19.0% from the last close, and Ticker Nerd's factor model ranks STAAR Surgical Co. 80 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering STAAR Surgical Co. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for STAA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $19 to $37 over the next 12 months.
STAAR Surgical Co. returned -16.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Staar Surgical Company designs, develops, manufactures, and sells implantable lenses for eye surgery, operating primarily in the ophthalmic medical devices sector. The company offers two main product categories: Implantable Collamer lenses (ICL) used in refractive surgery to correct vision problems without removing the eye's natural lens, and intraocular lenses (IOL) used in cataract surgery.
The most recent item we track (Zacks Investment Research, 17 Aug 2026): "Deciphering Staar Surgical (STAA) International Revenue Trends". Zacks Investment Research published a review of STAAR Surgical's (STAA) international revenue performance and how those trends influence Wall Street analysts' forecasts and the stock's future prospects.
Staar Surgical Company designs, develops, manufactures, and sells implantable lenses for eye surgery, operating primarily in the ophthalmic medical devices sector. The company offers two main product categories: Implantable Collamer lenses (ICL) used in refractive surgery to correct vision problems without removing the eye's natural lens, and intraocular lenses (IOL) used in cataract surgery. Staar Surgical delivers these products through specialized accessory delivery systems designed for surgical use. With over 2.5 million implants performed worldwide, the company serves ophthalmic surgeons and surgical centers globally. The ophthalmic surgical product segment generates the majority of Staar Surgical's revenue. Founded in 1982 and headquartered in Lake Forest, California, Staar Surgical operates as a medical device manufacturer focused on vision correction and cataract treatment solutions for healthcare providers and patients seeking surgical vision correction alternatives.
CEO Ms. Deborah J. Andrews · 921 employees · United States · https://www.staar.com